Skip to main content
Top
Published in: BMC Cancer 1/2011

Open Access 01-12-2011 | Erratum

Erratum to:Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas

Authors: Yosuke Hashimoto, Marek Skacel, Ian C Lavery, Abir L Mukherjee, Graham Casey, Josephine C Adams

Published in: BMC Cancer | Issue 1/2011

Login to get access

Excerpt

Correction [1]: It was recently brought to our attention that, although the statistical analyses in Table four had passed the original peer-review of this paper, the risk ratio and value of the lower 95% confidence interval for some of the variables in Table four were not consistent with the p values. We have repeated the multi-variant statistical analysis of the original data with StatView software. This analysis produced different values for the risk ratios and 95% confidence intervals for variables other than age. The corrected Table four is presented below (table 1). The p values are unchanged, thus the original conclusions of the article are not altered.
Table 1
Corrected table four
Table 4a. Cox's proportional hazard analysis in stage I-IV patients
Variables
Risk ratio (95% confidence Interval)
p
Age (≥ 65 yrs)
1.618 (0/944-2.774)
0.080
Gender (male)
1.626 (0.965-2.740)
0.068
Lymph node metastasis (N1, 2)
0.253 (0.146-0.439)
< 0.001*
Distant metastasis (M1)
0.581 (0.317-1.066)
0.797
Tumour location (distal)
0.963 (0.550-1.686)
0.894
Fascin (high)
0.548 (0.272-1.104)
0.925
Table 4b. Cox's proportional hazard analysis in stage III/IV patients
Variable
Risk ratio (95% confidence Interval)
p
Age (> 65 yrs)
1.259 (0.683-2.318)
0.460
Gender (male)
1.659 (0.886-3.108)
0.114
Lymph node metastasis (N1, 2)
1.032 (0.358-2.972)
0.934
Distant metastasis (M1)
0.803 (0.381-1.697)
0.566
Tumour location (distal)
0.683 (0.362-1.289)
0.240
Fascin (high)
0.435 (0.197-0.957)
0.039*
Metadata
Title
Erratum to:Prognostic significance of fascin expression in advanced colorectal cancer: an immunohistochemical study of colorectal adenomas and adenocarcinomas
Authors
Yosuke Hashimoto
Marek Skacel
Ian C Lavery
Abir L Mukherjee
Graham Casey
Josephine C Adams
Publication date
01-12-2011
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2011
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-11-488

Other articles of this Issue 1/2011

BMC Cancer 1/2011 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine